Reevaluation for clinical manifestations of HTLV-I-seropositive patients with Sjögren’s syndrome

BMC Musculoskeletal Disorders

Atsushi Kawakami⁶  Takashi Nakamura⁵  Junya Fukuoka³  Tatsufumi Nakamura⁴  Hirokazu Shiraishi¹  Shuntaro Sato²  Yoshikazu Nakashima⁶  Yoshiro Horai⁶  Yoshiko Takahashi⁶  Yukinori Takagi⁵  Toshimasa Shimizu⁶  Hideki Nakamura⁶ 

[1] Unit of Translational Medicine, Department of Clinical Neuroscience and Neurology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan;Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan;Department of Pathology, Nagasaki University Hospital, Nagasaki, Japan;Department of Human Community, Faculty of Social Welfare, Nagasaki International University, Nagasaki, Japan;Department of Radiology and Cancer Biology, Nagasaki University School of Dentistry, Nagasaki, Japan;Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City 852-8501, Nagasaki, Japan

关键词: Minor salivary gland biopsy;    AECG criteria;    HTLV-I;    Sjögren’s syndrome;   

Others  :  1234040
DOI  :  10.1186/s12891-015-0773-1

 received in 2015-06-16, accepted in 2015-10-14,  发布年份 2015

【 摘 要 】

Background

The aim of the study was to reassess the prevalence and characteristics of human T lymphotropic virus type I (HTLV-I)-associated Sjögren’s syndrome (SS) and SS in HTLV-I-associated myelopathy (HAM) based on the American European Consensus Group (AECG) criteria in HTLV-I endemic area, Nagasaki prefecture.

Methods

The 349 patients who underwent a minor salivary gland biopsy (MSGB) for suspected SS were retrospectively classified by AECG classification criteria and divided with or without anti-HTLV-I antibody.

Results

The HTLV-I data-available 294 patients were investigated. One hundred-seventy patients were classified as SS and 26.5 % were HTLV-I-seropositive. We have included 26 patients with HTLV-I-associated myelopathy (HAM) and 38.5 % were classified as having SS. The prevalences of ANA and anti-SS-A/Ro antibody of HAM + SS were significantly low compared to the HTLV-I asymptomatic carriers (AC) with SS and the HTLV-I-seronegative SS patients, although lacrimal dysfunction tended to be high in HAM + SS and significantly high in AC + SS patients compared with the patients with HTLV-I-seronegative SS. The focus scores of MSGB in the HAM + SS patients were similar to those of the AC + SS patients and the HTLV-I-seronegative patients with SS. Among the MSGB-positive patients, there was a low prevalence of ANA in the HAM + SS patients. Similar results were obtained in case of anti-SS-A/Ro or SS-B/La antibody.

Conclusion

In HTLV-I endemic area, high prevalence of anti-HTLV-I antibody among SS as well as the characteristics of HAM + SS and AC + SS was still determined by AECG classification criteria.

【 授权许可】

   
2015 Nakamura et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]Nakamura T. HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP): the role of HTLV-I-infected Th1 cells in the pathogenesis, and therapeutic strategy. Folia Neuropathol. 2009; 47:182-194.
• [2]Tsukasaki K, Tobinai K. Biology and treatment of HTLV-1 associated T-cell lymphomas. Best Pract Res Clin Haematol. 2013; 26:3-14.
• [3]Nakamura H, Kawakami A, Eguchi K. Mechanisms of autoantibody production and the relationship between autoantibodies and the clinical manifestations in Sjögren's syndrome. Transl Res. 2006; 148:281-288.
• [4]Fox RI. Sjögren’s syndrome. Lancet. 2005; 366(9482):321-331.
• [5]Miceli-Richard C, Criswell LA. Genetic, genomic and epigenetic studies as tools for elucidating disease pathogenesis in primary Sjögren’s syndrome. Expert Rev Clin Immunol. 2014; 10:437-444.
• [6]Terada K, Katamine S, Eguchi K, Moriuchi R, Kita M, Shimada H et al.. Prevalence of serum and salivary antibodies to HTLV-1 in Sjögren’s syndrome. Lancet. 1994; 344(8930):1116-1119.
• [7]Tangy F, Ossondo M, Vernant JC, Smadja D, Blétry O, Baglin AC et al.. Human T cell leukemia virus type I expression in salivary glands of infected patients. J Infect Dis. 1999; 179:497-502.
• [8]Sumida T, Yonaha F, Maeda T, Kita Y, Iwamoto I, Koike T et al.. Expression of sequences homologous to HTLV-I tax gene in the labial salivary glands of Japanese patients with Sjögren’s syndrome. Arthritis Rheum. 1994; 37:545-550.
• [9]Shattles WG, Brookes SM, Venables PJ, Clark DA, Maini RN. Expression of antigen reactive with a monoclonal antibody to HTLV-1 P19 in salivary glands in Sjögren’s syndrome. Clin Exp Immunol. 1992; 89:46-51.
• [10]Nakamura H, Eguchi K, Nakamura T, Mizokami A, Shirabe S, Kawakami A et al.. High prevalence of Sjögren’s syndrome in patients with HTLV-I associated myelopathy. Ann Rheum Dis. 1997; 56:167-172.
• [11]Nakamura H, Kawakami A, Tominaga M, Hida A, Yamasaki S, Migita K et al.. Relationship between Sjögren’s syndrome and human T-lymphotropic virus type I infection: follow-up study of 83 patients. J Lab Clin Med. 2000; 135:139-144.
• [12]Vitali C, Bombardieri S, Moutsopoulos HM et al.. Preliminary criteria for the classification of Sjögren’s syndrome: results of a prospective concerted action supported by European Community. Arthritis Rheum. 1993; 36:340-347.
• [13]Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE et al.. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002; 61:554-8.
• [14]Shiboski SC, Shiboski CH, Criswell L, Baer A, Challacombe S, Lanfranchi H et al.. American College of Rheumatology classification criteria for Sjögren’s syndrome: a data-driven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken). 2012; 64:475-487.
• [15]Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A et al.. HTLV-I associated myelopathy, a new clinical entity. Lancet. 1986; 1(8488):1031-1032.
• [16]Rubin P, Holt JF. Secretory sialography in disease of the major salivary gland. Am J Rentgenol. 1957; 77:575-598.
• [17]Chisholm DN, Mason DK. Labial salivary gland biopsy in Sjögren’s disease. J Clin Pathol. 1968; 21:656-660.
• [18]Greenspan JS, Daniels TE, Talal N, Sylvester RA. The histopathology of Sjögren’s syndrome in labial salivary gland biopsies. Oral Surg Oral Med Oral Pathol. 1974; 37:217-229.
• [19]Nakamura H, Kawakami A, Izumi M, Nakashima T, Takagi Y, Ida H et al.. Detection of the soluble form of Fas ligand (sFasL) and sFas in the saliva from patients with Sjogren’s syndrome. Clin Exp Rheumatol. 2005; 23:915.
• [20]Green JE, Hinrichs SH, Vogel J, Jay G. Exocrinopathy resembling Sjögren’s syndrome in HTLV-1 tax transgenic mice. Nature. 1989; 341(6237):72-74.
• [21]Hida A, Imaizumi M, Sera N, Akahoshi M, Soda M, Maeda R et al.. Association of human T lymphotropic virus type I with Sjogren syndrome. Ann Rheum Dis. 2010; 69:2056-2057.
• [22]Iwanaga M, Watanabe T, Utsunomiya A, Okayama A, Uchimaru K, Koh KR et al.. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood. 2010; 26(116):1211-1219.
• [23]Hisada M, Okayama A, Shioiri S, Spiegelman DL, Stuver SO, Mueller NE. Risk factors for adult T-cell leukemia among carriers of human T-lymphotropic virus type I. Blood. 1998; 92:3557-3561.
• [24]Nakamura H, Kawakami A, Hayashi T, Nakamura T, Iwamoto N, Yamasaki S et al.. Low prevalence of ectopic germinal centre formation in patients with HTLV-I-associated Sjogren’s syndrome. Rheumatology (Oxford). 2009; 48:854-855.
• [25]Ansel KM, Ngo VN, Hyman PL, Luther SA, Förster R, Sedgwick JD et al.. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature. 2000; 406(6793):309-314.
• [26]Shi K, Hayashida K, Kaneko M, Hashimoto J, Tomita T, Lipsky PE et al.. Lymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients. J Immunol. 2001; 166:650-655.
• [27]Nakamura H, Takahashi Y, Yamamoto-Fukuda T, Horai Y, Nakashima Y, Arima K et al.. Direct infection of primary salivary gland epithelial cells by human T lymphptropic virus type I in patients with Sjögren’s syndrome. Arthritis Rheumatol. 2015; 67:1096-1106.
• [28]Seror R, Mariette X, Bowman S, Baron G, Gottenberg JE, Bootsma H et al.. Accurate detection of changes in disease activity in primary Sjögren’s syndrome by the European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index. Arthritis Care Res (Hoboken). 2010; 62:551-558.
• [29]Seror R, Bootsma H, Saraux A, Bowman SJ, Theander E, Brun JG et al. Defining disease activity states and clinically meaningful improvement in primary Sjögren’s syndrome with EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis. 2014: Dec 5. [Epub ahead of print].